计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
A126073-1g |
1g |
现货 ![]() |
| |
A126073-5g |
5g |
现货 ![]() |
| |
A126073-25g |
25g |
现货 ![]() |
| |
A126073-100g |
100g |
现货 ![]() |
| |
A126073-500g |
500g |
期货 ![]() |
|
别名 | 阿昔洛韦 | 无环鸟苷 | 9-[(2-羟基乙氧基)甲基]鸟嘌呤 | 阿昔洛维 | 开糖环鸟苷 | 羟乙氧甲鸟嘌呤 | 无环鸟嘌呤核苷 | 无环鸟嘌呤 |
---|---|
英文别名 | acyclovir | Aciclovir | Acycloguanosine | 59277-89-3 | Zovirax | Virorax | Vipral | Wellcome-248U | Aciclovirum | 9-[(2-Hydroxyethoxy)methyl]guanine | Sitavig | Zovir | 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one | Gerpevir | Hascovir | Acyclovir-side chain-2-3H | Aciclovirum |
规格或纯度 | Moligand™, ≥99% |
英文名称 | Aciclovir |
生化机理 | Acyclovir is an antiviral compound that can be used to induce apoptosis in cells transfected with herpes simplex virus thymidine kinase (HSV-TK). The compound may exert inhibitory effects throμgh the alterations of the cell cycle in leukemia cells lines, such as p185BCR-ABL expressing OM9;22 cells, by synchronizing the G0/G1 phase. Formation of acycloguanosine triphosphate occurs throμgh the phosphorylation of HSV-TK and can inhibit the viral DNA polymerase. Acyclovir also has the ability to inhibit the proliferation of the fibroblast cells, NIH 3T3, transformed with v-abl or bcr-abl.Guanosine derivative, competitively inhibits viral DNA polymerase. High specificity for herpes simplex 1 and 2 (EC 50 values are 0.04 and 0.44 μM, respectively) and varicella-zoster viruses (IC 50 = 0.22 μM). |
应用 | An antiviral compound that can be used to induce apoptosis. |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 人类疱疹病毒 1 DNA 聚合酶抑制剂 |
备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
产品介绍 |
Acyclovir 是一种合成的核苷类似物,有效作用于疱疹病毒。 Aciclovir is a synthetic nucleoside analogue active against herpesviruses. |
PubChem SID | 488202820 |
---|---|
IUPAC Name | 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one |
INCHI | InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15) |
InChi Key | MKUXAQIIEYXACX-UHFFFAOYSA-N |
Canonical SMILES | C1=NC2=C(N1COCCO)N=C(NC2=O)N |
Isomeric SMILES | C1=NC2=C(N1COCCO)N=C(NC2=O)N |
WGK Germany | 2 |
RTECS | UP0791400 |
PubChem CID | 135398513 |
分子量 | 225.2 |
Reaxy-Rn | 1219402 |
溶解性 | Soluble in water (partly), DMSO (50 mg/ml), DMF (1 mg/ml), 1eq. HCl (50 mM), and dilute alkalies. |
---|---|
熔点 | 262°C |
分子量 | 225.200 g/mol |
XLogP3 | -1.900 |
氢键供体数Hydrogen Bond Donor Count | 3 |
氢键受体数Hydrogen Bond Acceptor Count | 5 |
可旋转键计数Rotatable Bond Count | 4 |
精确质量Exact Mass | 225.086 Da |
单同位素质量Monoisotopic Mass | 225.086 Da |
拓扑极表面积Topological Polar Surface Area | 115.000 Ų |
重原子数Heavy Atom Count | 16 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 308.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
WGK Germany | 2 |
---|---|
RTECS | UP0791400 |
Reaxy-Rn | 1219402 |
Merck Index | 146 |
个人防护装备 | Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 24-12-06 | A126073 |
![]() |
分析证书 | 24-12-06 | A126073 |
![]() |
分析证书 | 24-12-06 | A126073 |
![]() |
分析证书 | 24-12-06 | A126073 |
![]() |
分析证书 | 24-07-23 | A126073 |
![]() |
分析证书 | 24-07-23 | A126073 |
![]() |
分析证书 | 24-07-23 | A126073 |
![]() |
分析证书 | 24-07-23 | A126073 |
![]() |
分析证书 | 24-06-27 | A126073 |
![]() |
分析证书 | 24-05-31 | A126073 |
![]() |
分析证书 | 24-05-31 | A126073 |
![]() |
分析证书 | 24-05-31 | A126073 |
![]() |
分析证书 | 23-05-10 | A126073 |
![]() |
分析证书 | 22-09-20 | A126073 |
![]() |
分析证书 | 22-06-23 | A126073 |
![]() |
分析证书 | 22-06-23 | A126073 |
![]() |
分析证书 | 22-06-23 | A126073 |
![]() |
分析证书 | 22-06-23 | A126073 |
![]() |
分析证书 | 22-06-23 | A126073 |
1. Datta AK, Colby BM, Shaw JE, Pagano JS. (1980) Acyclovir inhibition of Epstein-Barr virus replication.. Proc Natl Acad Sci USA, 77 (9): (5163-6). [PMID:6254061] [10.1021/op500134e] |
2. Allaudeen HS, Descamps J, Sehgal RK. (1982) Mode of action of acyclovir triphosphate on herpesviral and cellular DNA polymerases.. Antiviral Res, 2 (3): (123-33). [PMID:6291456] [10.1021/op500134e] |
3. Gnann Jr JW, Barton NH, Whitley RJ. (1983) Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications.. Pharmacotherapy, 3 (5): (275-83). [PMID:6359082] [10.1021/op500134e] |
1. Datta AK, Colby BM, Shaw JE, Pagano JS. (1980) Acyclovir inhibition of Epstein-Barr virus replication.. Proc Natl Acad Sci USA, 77 (9): (5163-6). [PMID:6254061] [10.1021/op500134e] |
2. Allaudeen HS, Descamps J, Sehgal RK. (1982) Mode of action of acyclovir triphosphate on herpesviral and cellular DNA polymerases.. Antiviral Res, 2 (3): (123-33). [PMID:6291456] [10.1021/op500134e] |
3. Gnann Jr JW, Barton NH, Whitley RJ. (1983) Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications.. Pharmacotherapy, 3 (5): (275-83). [PMID:6359082] [10.1021/op500134e] |